The peptides that make saliva heal mouths — real, receptor-mediated wound biology in vitro, and a human evidence base that is much thinner than the marketing suggests.
Histatins are a family of histidine-rich peptides secreted into human saliva by the parotid and submandibular glands. They are the main reason a cut inside your mouth heals faster than the same cut on your skin — saliva is not just moisture, it carries its own wound-response chemistry.
The family was defined by Oppenheim and colleagues in 1988 (PMID 3286634). The three principal members are histatin 1 (38 amino acids), histatin 3 (32 amino acids) and histatin 5 (24 amino acids), encoded by the genes HTN1 and HTN3 and each carrying seven histidine residues. Histatin 5 is not separately gene-encoded — it is a proteolytic fragment cut from histatin 3, which matters for how the family divides its labour: the larger histatins are primarily the wound-closure molecules, while histatin 5 became the family's antifungal specialist.
Histatins are genuinely unusual among the compounds in this library: they are endogenous human peptides with a defined physiological job, their mechanisms have been worked out to an unusual depth for a research peptide — and yet no histatin product is approved as a drug anywhere in the world. This guide covers both the elegant biology and the stalled translation.
Not approved anywhere. Human data: one modest mouthwash trial and one completed-but-unpublished Phase II. Everything else is cell culture and animal work.
Fractionating human saliva showed that histatins 1 and 2 are the components responsible for saliva's wound-closure activity (Oudhoff et al. 2008, FASEB Journal, PMID 18650243). They close experimental wounds by making epithelial cells migrate and spread across the gap via ERK1/2 signalling — not by making them divide. A follow-up study confirmed there is no proliferative effect (PMID 19652025). Closure-by-migration is a meaningful distinction: it is a re-covering mechanism, not a growth signal.
The cleanest evidence that histatins act through a specific receptor rather than by generic membrane effects: the mirror-image D-form of histatin 2 is inactive (PMID 18650243). A membrane-disruption mechanism would not care about handedness; a receptor does. The minimal active sequence was mapped to a short internal domain (SHREFPFYGDYGS), and cyclising that fragment increased its molar potency roughly a thousand-fold (PMID 19652025). A candidate receptor — the sigma-2 receptor, TMEM97 — was proposed in 2021 (PMID 34233061), from a single research group so far.
Histatin 1 promotes epithelial cell adhesion (half-maximal around 1 µM) and raised transepithelial electrical resistance — a direct measure of barrier tightness — by about 20 percent at 10 µM (PMID 25903106), with supporting work on the junction proteins ZO-1 and E-cadherin (PMID 28522595). It also promotes angiogenesis in vitro and in the chick chorioallantoic membrane assay, through a RIN2 to Rab5 to Rac1 pathway (PMID 28751526). These are coherent, mutually reinforcing cell-biology findings — all still preclinical.
Histatin 5 does not punch holes in Candida. It binds specific fungal cell-wall receptors (Ssa1/2; binding Kd around 2.57 µM), is transported inside by the Dur3/Dur31 uptake proteins, and targets the energised mitochondrion, causing a non-lytic release of ATP that kills the cell (PMIDs 12761219, 22033918, 10066791, 10383383). This receptor-and-transporter pathway is why the antifungal effect is selective for fungi over human cells — and why it is fragile in ways the next section details.
| Claimed benefit | Evidence |
|---|---|
| Wound closure | Strong in vitro mechanism (migration, stereospecific, mapped active domain; PMIDs 18650243, 19652025). No human wound trial of any histatin exists. |
| Anti-Candida activity | Robust in low-salt laboratory conditions (MIC₅₀ roughly 5–20 µg/mL; PMID 24951439). Markedly weakened by physiological salt — the key caveat. |
| Oral health (gingivitis) | One randomised trial of a P-113 mouth rinse, n=159: plaque improved (p=0.046), gingivitis did not reach significance (p=0.086), no dose-response (PMID 11350502). |
| Corneal healing | In vitro only (PMID 28542418). No human eye trial. |
| Dental implant integration | In vitro adhesion work on titanium surfaces only (PMID 27941125). |
| Angiogenesis | In vitro plus chick membrane assay (PMID 28751526). No human data. |
Build your protocol, log every dose, monitor your body's response, and get reminders so you never miss a dose.
Start Tracking FreeHistatin 5's antifungal mechanism is one of the best-characterised of any antimicrobial peptide — which makes its central weakness easy to state precisely, because the literature documented it itself.
The weakness is salt. Histatin 5's killing requires an energised fungal mitochondrion and is inhibited by physiological salt concentrations and by azide (PMID 10066791). The standard summary of the field (Puri and Edgerton 2014, PMID 24951439) reports half-maximal inhibitory concentrations around 5 to 20 µg/mL — measured in low-salt assay conditions. Human body fluids are not low-salt. Any claim for histatin antifungal potency that does not mention the assay conditions is leaving out the variable that decides whether the effect survives contact with a real tissue environment.
The fungus fights back, and sometimes wins. Candida albicans secretes a protease, Sap9, that degrades histatin 5 — and histatin 5 levels are measurably reduced in the saliva of HIV-positive patients, one proposed contributor to their susceptibility to oral candidiasis (PMID 19352427). The peptide is a participant in an ongoing host-pathogen contest, not a one-sided weapon.
A literature dispute, preserved. A 2001 paper reported that histatin 5 kills via reactive oxygen species (PMID 11717389). A 2004 paper concluded the ROS signal was an artefact of the assay (PMID 15109304). This guide prints both because that is what the record contains; vendor summaries that cite the 2001 mechanism as settled are three years out of date relative to their own citation.
The fragment that became a drug candidate. P-113 is a 12-amino-acid fragment of histatin 5 (residues 4–15). Its all-D mirror form is fully active (PMID 11302797) — the opposite pattern from histatin 2's wound activity, telling you the antifungal uptake machinery tolerates either handedness while the wound-closure receptor does not. P-113 is the molecule that went into human testing, covered next.
The complete human trial record for histatins, as of this guide, fits in this section.
A randomised trial of a P-113 mouth rinse in 159 adults. At the 0.01% concentration, plaque scores improved significantly versus control (p=0.046); the gingivitis endpoint did not reach significance (p=0.086); a five-fold higher concentration (0.05%) showed no dose-response advantage; and there were no treatment-related adverse events. Read fairly: a real but small and internally inconsistent result — one endpoint positive, the headline endpoint not, no dose gradient — for a mouth rinse, not a drug effect.
PAC-113 (the P-113 formulation) completed a Phase IIb trial in oral candidiasis — 223 patients, registered as NCT00659971. The sponsor announced success in a press release. The results were never published in a journal and never posted to the trial registry, no Phase III followed, and no histatin product has been approved anywhere. A completed trial with unreported results is not evidence of efficacy; in the evidence hierarchy it is closer to a gap. Anyone citing "Phase II-proven" histatin antifungal efficacy is citing a press release.
The only commercial afterlife is cosmetic: P113+ oral-care products sold over the counter in Taiwan. Cosmetic sale is not drug approval and involves no efficacy adjudication. There are no human trials of histatins for skin wounds, eye drops, or implant coatings — those applications exist as cell studies, conference abstracts and patents.
Pre-filled with a typical Histatins setup. Edit any field — the draw updates live.
Insulin syringe — 100 units = 1 mL
Free account. Saves your reconstitution + schedules doses + tracks every vial.
Dosing cheat sheet, reconstitution reference, and cycle planning — delivered to your inbox.
Histatins are endogenous — your salivary glands secrete them continuously — and the one completed human trial programme (an oral rinse) reported no treatment-related adverse events (PMID 11350502). On the available record, local oral exposure at cosmetic-type concentrations appears benign.
There is no human safety data for injected histatins, for histatin wound gels, eye preparations, or any systemic use — those exposures have simply never been trialled. Endogenous presence in saliva does not establish safety at pharmacological doses by other routes; insulin and melittin are also endogenous or natural, with very different risk profiles. No dosing protocol section appears in this guide because there is no human dosing literature to summarise: no established dose, route, or regimen exists for any histatin product. Research-grade histatin powders are sold for laboratory use, and their certificates carry only what a COA can prove — see the Basics guide on purity testing.
Histatins is a research peptide not approved by the FDA for human use. It is sold only as a research chemical, and StackTrax does not endorse or facilitate personal use.
Quality varies enormously among research-chemical suppliers. At minimum, look for:
Lyvn does not carry Histatins. They are the vendor we recommend elsewhere on this site, and they publish the full independent panel per batch — which makes their catalogue a useful yardstick for the criteria above even on a compound they do not stock. We are not recommending a specific supplier for Histatins itself, because we have no basis to.
For research use only. Not for human consumption. 21+.
Build your protocol, log every dose, monitor your body's response, and get reminders so you never miss a dose.
Start Tracking FreeThey are saliva's built-in response team. Histatins 1 and 2 drive the re-covering of wounds in the mouth by making epithelial cells migrate across the damage — the reason oral wounds heal unusually fast — while histatin 5 is an antifungal that is taken up by Candida cells and kills them from inside via their mitochondria (PMIDs 18650243, 12761219). They are secreted continuously by the salivary glands.
No. No histatin or histatin-fragment product holds a drug approval in any major jurisdiction. The fragment P-113 survives commercially only as an ingredient in over-the-counter oral-care cosmetics in Taiwan, which are not efficacy-regulated like drugs.
In laboratory conditions, yes — histatin 5 kills Candida albicans at roughly 5 to 20 µg/mL. The condition matters: those assays are run at low salt, and physiological salt concentrations markedly weaken the effect (PMIDs 10066791, 24951439). Candida also degrades histatin 5 with its Sap9 protease (PMID 19352427). The clinical translation — a Phase IIb trial of PAC-113 in 223 patients — was never published, so human antifungal efficacy is unproven either way.
P-113 is a 12-amino-acid fragment of histatin 5 (residues 4 to 15) developed as an antifungal. It was tested as a mouth rinse for gingivitis in 159 people with mixed results (PMID 11350502), and as PAC-113 in a 223-patient Phase IIb oral candidiasis trial (NCT00659971) whose results were announced by press release but never published or posted to the registry. No Phase III followed.
That has never been tested in a human trial. The wound-closure evidence is cell culture and animal-model work — strong mechanistic work, including proof of a stereospecific receptor and a mapped minimal active sequence (PMIDs 18650243, 19652025) — plus in-vitro studies for cornea and dental implant surfaces. Interesting is not the same as demonstrated, and this is the gap between the histatin literature and histatin marketing.
For the exposure that has actually been studied — oral rinses at low concentration — the trial record shows no treatment-related adverse events (PMID 11350502), and the peptides are endogenous to saliva. Beyond that, honesty requires a blank page: injected, ocular, wound-applied and systemic histatin use have no human safety data at all, and endogenous presence at salivary concentrations does not certify pharmacological doses by other routes.
Disclaimer: This guide is for educational and informational purposes only and is not intended as medical advice, diagnosis, or treatment. The compounds discussed are not FDA approved for human use. Always consult a qualified healthcare provider before starting any new supplement or peptide protocol. StackTrax does not sell peptides or supplements directly — purchase links go to third-party vendors. StackTrax is not responsible for the products, quality, or business practices of any third-party vendor.
© 2026 StackTrax, LLC. All rights reserved.
Privacy · Terms · Do Not Sell or Share My Personal Information
StackTrax guides cover peptides and compounds that are not FDA-approved for the uses discussed. The dosing, reconstitution, and safety information is compiled from published research and community protocols for educational purposes only.
Before using any compound mentioned here, consult a qualified healthcare provider. StackTrax does not sell, prescribe, or recommend these substances for personal use.